Stonegate Investment Group, LLC Biocryst Pharmaceuticals Inc Transaction History
Stonegate Investment Group, LLC
- $3.64 Billion
- Q4 2024
A detailed history of Stonegate Investment Group, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Stonegate Investment Group, LLC holds 49,688 shares of BCRX stock, worth $415,391. This represents 0.01% of its overall portfolio holdings.
Number of Shares
49,688
Previous 49,588
0.2%
Holding current value
$415,391
Previous $376,000
0.8%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding BCRX
# of Institutions
278Shares Held
167MCall Options Held
728KPut Options Held
989K-
Vanguard Group Inc Valley Forge, PA21.9MShares$183 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$167 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$99.2 Million1.3% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$76 Million4.33% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$68.1 Million1.52% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.55B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...